Pharmacy Times February 3, 2025
Naga Vara Kishore Pillarsetty, PhD, discusses advancements in radiopharmaceuticals for cancer therapy, noting common supply chain challenges, radiation safety measures, and patient misconceptions with the use of these drugs.
Pharmacy Times interviewed Naga Vara Kishore Pillarsetty, PhD, a radiochemist at Memorial Sloan Kettering Cancer Center, about his presentation at Precision Medicine World Conference 2025 which discusses radiopharmaceuticals for cancer therapy. Kishore Pillarsetty explains that radiopharmaceuticals play a critical role in treating various cancers, with radioactive iodine therapy for thyroid cancer being the first targeted treatment. More recent advancements include Lutetium-177 (Lu 177)-dotatate (Lutathera;Novartis) for neuroendocrine tumors and Lu 177 vipivotide tetraxetan (Pluvicto; Novartis) for PSMA-positive (PSMA+) prostate cancer.
Kishore Pillarsetty notes that radiopharmacists work closely with chemists, oncologists, and nuclear...
Today's Sponsors
Today's Sponsor